Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199

被引：1
|
作者：
Sparano, J. A.
Wang, M.
Martino, S.
Jones, V.
Perez, E.
Saphner, T.
Wolff, A. C.
Sledge, G. W., Jr.
Wood, W. C.
Davidson, N. E.
机构：
[1] Eastern Cooperat Oncol Grp, Brookline, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Southwest Oncol Grp, Ann Arbor, MI USA
[4] Canc & Acute Leukemia Grp B, Chicago, IL USA
[5] North Cent Canc Treatment Grp, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
    Yifan Tu
    Dawn L. Hershman
    Kapil Bhalla
    Warren Fiskus
    Christine M. Pellegrino
    Eleni Andreopoulou
    Della Makower
    Kevin Kalinsky
    Karen Fehn
    Susan Fineberg
    Abdissa Negassa
    Leslie L. Montgomery
    Lisa S. Wiechmann
    R. Katherine Alpaugh
    Min Huang
    Joseph A. Sparano
    Breast Cancer Research and Treatment, 2014, 146 : 145 - 152
  • [32] Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial
    Nabholtz, JM
    Falkson, C
    Campos, D
    Szanto, J
    Martin, M
    Chan, S
    Pienkowski, T
    Zaluski, J
    Pinter, T
    Krzakowski, M
    Vorobiof, D
    Leonard, R
    Kennedy, I
    Azli, N
    Murawsky, M
    Riva, A
    Pouillart, P
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 968 - 975
  • [33] SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer
    Ellis, G. K.
    Barlow, W. E.
    Russell, C. A.
    Royce, M. E.
    Perez, E. A.
    Livingston, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 933S - 933S
  • [34] Phase I-II study of the histone deacetytase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
    Tu, Yifan
    Hershman, Dawn L.
    Pellegrino, Christine M.
    Andreopoulou, Eleni
    Makower, Della
    Fineberg, Susan
    Bhalla, Kapil N.
    Kalinsky, Kevin
    Fehn, Karen
    Huang, Min
    Alpaugh, R. Katherine
    Sparano, Joseph A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] A phase 2 trial of myocet®, cyclophosphamide plus /- trastuzumab followed by weekly paclitaxel plus /- trastuzumab as primary systemic therapy in operable and locally advanced breast cancer
    Pistilli, B.
    Rossi, D.
    Benedetti, G.
    Baldelli, A. M.
    Decembrini-Cognigni, P.
    Casadei, V.
    Ciccioli, G.
    Ranaldi, R.
    Fiorentini, G.
    Latini, L.
    CANCER RESEARCH, 2013, 73
  • [36] Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients:: BCIRG 006 study
    Slamon, D
    Eiermann, W
    Robert, N
    Pienkowski, T
    Martin, M
    Pawlicki, M
    Chan, A
    Smylie, M
    Liu, M
    Falkson, C
    Pinter, T
    Fornander, T
    Shiftan, T
    Valero, V
    Von Minckwitz, G
    Mackey, J
    Tabah-Fisch, J
    Buyse, M
    Lindsay, MA
    Riva, A
    Bee, V
    Pegram, M
    Press, M
    Crown, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S5 - S5
  • [37] Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study
    Cognetti, F.
    Bruzzi, P.
    De Placido, S.
    De laurentiis, M.
    Boni, C.
    Aitini, E.
    Durando, A.
    Turletti, A.
    Valle, E.
    Garrone, O.
    Puglisi, F.
    Montemurro, F.
    Barni, S.
    Di Blasio, B.
    Gamucci, T.
    Colantuoni, G.
    Olmeo, N.
    Tondini, C.
    Parisi, A. M.
    Bighin, C.
    Pastorino, S.
    Lambertini, M.
    Del Mastro, L.
    CANCER RESEARCH, 2013, 73
  • [38] Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Sofyan M. Radaideh
    George W. Sledge
    Breast Cancer Research and Treatment, 2008, 111 : 203 - 208
  • [39] Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Radaideh, Sofyan M.
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 111 (02) : 203 - 208
  • [40] Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients:: results of a phase II study
    Estevez, L. G.
    Sanchez-Rovira, P.
    Domine, M.
    Leon, A.
    Calvo, I.
    Jaen, A.
    Casado, V.
    Rubio, G.
    Diaz, M.
    Miro, C.
    Lobo, F.
    Carrasco, E.
    Casillas, M.
    Antonio, B. San
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (05): : 317 - 322
12345